IP Library Patent Application 10970815
Patent Application
App. No. 10/970,815

Medicinal targeted local lipolysis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/970,815
Abstract

Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.

Claims (19)

1 . A method for the treatment of an adipose tissue disorder comprising the administration of an efficacious amount of an aqueous phospholipid system comprising

a) at least one phospholipid,

b) at least one bile acid and

c) water.

2 . The method of claim 1 , wherein said phospholipid is selected from the group consisting of 3-sn-phosphatidylcholine, soya, 3-sn-phosphatidylcholine, reduced soya, 3-(3sn)-phospohatidyl)glycerol soya, dimyristoylphosphatidylglycerol, lyso-phosphatidylcholine, and dipalmitoylphosphatidylglycerol, or the physiologically tolerated salts thereof, or a mixture thereof.

3 . The method of claim 2 , wherein the phospholipid is a physiologically tolerated sodium, potassium or ammonium salt.

4 . The method of claim 2 , wherein the phospholipid comprises soybean phosphatidylcholine.

5 . The method of claim 4 , wherein the phospholipid comprises at least 90 percent by weight soybean phosphatidylcholine.

6 . The method of claim 1 , wherein said bile acid is selected from the group consisting of deoxycholic acid, cholic acid, lithocholic acid, chenodeocycholic acid, hyodeoxycholic acid, trihydroxycoprostanic acid, ursodeoxycholic acid, taurocholic acid, and glycocholic acid, or the physiologically tolerated salts thereof, or a mixture thereof.

7 . The method of claim 6 , wherein the bile acid is a physiologically tolerated sodium, potassium or ammonium salt.

8 . The method of claim 1 , wherein the mass ratio of phospholipid to bile acid in percent by weight is from 30:1 to 1:0.03.

9 . The method of claim 1 , wherein the phospholipid concentration is from 0.5% by weight to 30% by weight.

10 . The method of claim 1 , wherein the adipose tissue disorder is a lipoma, Dercum's disease, Madelung's neck, lipedema, xanthelasama or piezogenic nodules.

11 . The method of claim 1 , wherein the adipose tissue disorder is adipose tissue tumors.

12 . A method for the treatment of cellulite comprising the administration of an efficacious amount of an aqueous phospholipid system comprising

a) at least one phospholipid,

b) at least one bile acid, and

c) water.

13 . A method for the treatment of cellulite comprising the administration of an efficacious amount of an aqueous phospholipid system comprising at least one phospholipid or at least one bile acid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2008
From: SANOFI-AVENTIS DEUTSCHLAND GMBH
To: MERZ PHARMACEUTICALS GMBH
Reel/Frame 020423/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2008
From: SANOFI-AVENTIS DEUTSCHLAND GMBH
To: MERZ PHARMACEUTICALS GMBH
Reel/Frame 020444/0240 →
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2005
From: BODERKE, DR. PETER; POOTH, DR. RAINER; SANDOW, DR. JUERGEN; GOSSEL, DR. MATTHIAS; NIETSCH, DR. KARL-HEINZ; SATTLER, DR. GERHARD; VOGEL, PROF GERHARD
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 015522/0708 →